BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20824907)

  • 21. Investigational treatments for multiple myeloma.
    Bringhen S; Avonto I; Magarotto V; Boccadoro M; Palumbo A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1565-82. PubMed ID: 17107282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib and lenalidomide effective in myeloma.
    Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
    [No Abstract]   [Full Text] [Related]  

  • 24. New treatments in multiple myeloma: beyond optimal treatment.
    Harousseau JL
    Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of double-refractory multiple myeloma.
    Meadows JP; Mark TM
    Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib.
    Paramore A; Frantz S
    Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
    [No Abstract]   [Full Text] [Related]  

  • 27. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M
    Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
    Ito C; Aisa Y; Mihara A; Nakazato T
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):83-5. PubMed ID: 23103083
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
    Laubach JP; Mitsiades CS; Roccaro AM; Ghobrial IM; Anderson KC; Richardson PG
    Leuk Lymphoma; 2009 May; 50(5):694-702. PubMed ID: 19452315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatments for myeloma.
    Azaïs I; Brault R; Debiais F
    Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma: novel approaches for relapsed disease.
    Lonial S
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular targeting therapy for multiple myeloma].
    Takatoku M
    Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.